RxDoctor Payments Data

Sunmin Park, MD

Ophthalmology · Los Angeles, CANPI 1871520601

Payments from drug & device makers

$4,941in general payments, 2019–2025

Across 256 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Aerie Pharmaceuticals, Inc.$697
  • Bausch & Lomb Americas Inc.$398
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$359
  • Oyster Point Pharma, Inc.$226
  • plus $913 from 12 others

What the payments were for

  • Food & beverage$4,941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,941 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$232,101
Medicare patients
545
Services billed
1,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,450$599,881
XiidraLifitegrast707$566,040
MieboPerfluorohexyloctane/Pf369$333,563
RestasisCyclosporine411$318,321
TyrvayaVarenicline Tartrate281$216,130
CequaCyclosporine233$153,886
LumiganBimatoprost449$129,455
Cyclosporine295$116,123
VyzultaLatanoprostene Bunod264$81,127
Icosapent Ethyl419$80,397
RocklatanNetarsudil Mesylat/Latanoprost117$48,847
ProlensaBromfenac Sodium117$45,949
CombiganBrimonidine Tartrate/Timolol176$44,880
Alphagan PBrimonidine Tartrate110$39,166
RhopressaNetarsudil Mesylate82$28,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$398$980,7301,340 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,344$531,8221,146 claims
Oyster Point Pharma, Inc.Tyrvaya$226$216,130281 claims
Sun Pharmaceutical Industries Inc.Cequa$1,004$153,886233 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$697$77,407199 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Alrex, Besivance$359$56,921151 claims
Eyevance Pharmaceuticals LLCZerviate$56$9,59123 claims
NovartisIlevro$102$7,25416 claims
Kala Pharmaceuticals, Inc.Eysuvis$54$5,90612 claims
AlconSimbrinza$138$5,71720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →